Skip to content

Exploratory Study on Lysimachia Christinae Hance(Jin-Qian-Cao)Combined with a Novel Quadruple Therapy in Patients with Ischemic Cardiomyopathy Complicated by Heart Failure and Urinary Tract Stones: A Double-Blind, Randomized Controlled Clinical Trial

Exploratory Study on Lysimachia Christinae Hance(Jin Qian Cao) Combined with a Novel Quadruple Therapy in Patients with Ischemic Cardiomyopathy Complicated by Heart Failure and Urinary Tract Stones

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500100117
Enrollment
Unknown
Registered
2025-04-02
Start date
2021-04-08
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiovascular medicine

Interventions

Control Group:Novel quadruple therapy for heart failure plus placebo.
Intervention Group:Novel quadruple therapy for heart failure plus Lysimachia christinae granules.

Sponsors

Guidong People’s Hospital of Guangxi Zhuang Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 85 Years

Inclusion criteria

Inclusion criteria: Participants aged between 30 and 85 years, regardless of gender, who meet the diagnostic criteria for ischemic cardiomyopathy (ICM) complicated by heart failure (HF) as defined in the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024, will be eligible for inclusion. Additionally, participants must have a confirmed diagnosis of urolithiasis based on imaging (ultrasound or CT), a cardiac function classification of NYHA class II to IV, stable vital signs including blood pressure and heart rate, and the ability to tolerate oral medication. All participants must provide written informed consent before enrollment in the study.

Exclusion criteria

Exclusion criteria: Exclusion criteria include: having undergone surgical intervention or extracorporeal shock wave lithotripsy (ESWL) for urolithiasis within the past three months; presence of other severe organic heart diseases (e.g., hypertrophic cardiomyopathy, valvular heart disease); significant hepatic or renal dysfunction (e.g., ALT or AST > 3 times the upper limit of normal, serum creatinine > 265 µmol/L); concurrent active infections, malignancies, or autoimmune diseases; participation in other clinical drug trials within the past month; known allergy to Lysimachia christinae or any components of the quadruple-drug regimen; pregnancy, lactation, or plans to become pregnant; and any other condition deemed unsuitable for study participation by the investigator.

Design outcomes

Primary

MeasureTime frame
Cardiac Function Parameters;urinary stone expulsion rate;

Secondary

MeasureTime frame
inflammatory factors;renal function;

Countries

China

Contacts

Public ContactCen Kaiyuan

Guidong People’s Hospital of Guangxi Zhuang Autonomous Region

cky163163@163.com+86 158 0774 2254

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026